- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05976763
Testen der kontinuierlichen versus intermittierenden Behandlung mit dem Studienmedikament Zanubrutinib bei älteren Patienten mit zuvor unbehandeltem Mantelzell-Lymphom
Eine randomisierte Phase-3-Studie zur kontinuierlichen vs. intermittierenden Erhaltungstherapie mit Zanubrutinib als Vorbehandlung bei älteren Patienten mit Mantelzell-Lymphom
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Verfahren: Biospecimen Collection
- Biologisch: Rituximab
- Verfahren: Computed Tomography
- Verfahren: Magnetic Resonance Imaging
- Sonstiges: Questionnaire Administration
- Verfahren: Positron Emission Tomography
- Verfahren: Colonoscopy
- Sonstiges: Patient Observation
- Verfahren: Esophagogastroduodenoscopy
- Arzneimittel: Zanubrutinib
- Verfahren: Bone Marrow Biopsy
- Sonstiges: Fludeoxyglucose F-18
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To compare time to first progression or death (progression free survival [PFS]1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B).
KEY SECONDARY OBJECTIVE:
I. To compare overall survival between patients who achieve a complete remission (CR) with induction therapy subsequently treated with continuous treatment versus (vs.) intermittent treatment as part of maintenance therapy.
SECONDARY OBJECTIVES:
I. To determine overall response rate (ORR) and CR rate to induction therapy with zanubrutinib and rituximab in previously untreated MCL.
II. To determine adverse events during induction and post-induction in each study arm (Arm A and B) by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.
III. To determine PFS1, event free survival (EFS) and overall survival (OS) in each study arm (A and B).
IV. To determine the overall response rate (ORR) and complete response rate (CR) after restarting zanubrutinib, following the first progression, in the intermittent treatment arm (Arm B).
V. To compare burden of symptomatic adverse events (AEs) as assessed by Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to Arm A versus Arm B.
QUALITY OF LIFE PRIMARY OBJECTIVE:
I. To compare health-related quality of life (QOL) at 12 months post-randomization as assessed by the Functional Assessment of Cancer Therapy (FACT) Lymphoma Symptom Index-18 (FLYMSI-18) total score between patients randomized to Arm A versus Arm B.
QUALITY OF LIFE SECONDARY OBJECTIVES:
I. To compare health-related QOL at other time points as assessed by the FLYMSI-18 total score between patients randomized to Arm A versus Arm B.
II. To compare burden of symptomatic AEs as assessed by PRO-CTCAE between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.
QUALITY OF LIFE EXPLORATORY OBJECTIVES:
I. To compare the geriatric functional and cognitive PRO as assessed by Elderly Functional Index (ELFI) and Neurology (Neuro) QOL in Arm A versus Arm B.
II. To compare cognitive function at various time points as assessed by the Neuro-QOL between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.
EXPLORATORY OBJECTIVES:
I. To evaluate the completion rate of a lymphoma-specific patient assessment of life survey (PALS) with patient directed questions on life, health, and social determinants of health (SDH) and assess the impact of the survey collected data on outcomes for all enrolled patients (study arms A and B).
II. To evaluate minimal residual disease (MRD) in those patients who achieve a CR after induction therapy (arms A and B) and how detectable MRD status changes after continued therapy vs. discontinuation of therapy (i.e. arms A vs. B).
OUTLINE:
INDUCTION THERAPY: Patients receive zanubrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle and rituximab intravenously (IV) on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. . Patients undergo bone marrow biopsy and fluciclovine F18 (FDG) positron emission tomography (PET)/ computed tomography (CT) or CT throughout the trial. Patients may also undergo esophagogastroduodenoscopy (EGD) and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.
MAINTENANCE THERAPY: Patients achieving a CR after induction therapy are randomized to 1 of 2 arms.
ARM A: Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until first disease progression on study. Patients undergo CT or magnetic resonance imaging (MRI) or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
ARM B: Patients undergo observation until first disease progression and then receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial and may undergo bone marrow biopsy on study.
After completion of study treatment, patients are followed within 30 days and every 6 months for 10 years.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Destin Carlisle
- Telefonnummer: 773-702-8824
- E-Mail: dcarlisle@bsd.uchicago.edu
Studieren Sie die Kontaktsicherung
- Name: Anne Beaven, MD
- Telefonnummer: 919-966-9268
- E-Mail: anne_beaven@med.unc.edu
Studienorte
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- Rekrutierung
- University of Arkansas for Medical Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-686-8274
-
Hauptermittler:
- Cesar Gentille
-
-
California
-
Beverly Hills, California, Vereinigte Staaten, 90211
- Rekrutierung
- Tower Cancer Research Foundation
-
Hauptermittler:
- Justin M. Darrah
-
Kontakt:
- Site Public Contact
- E-Mail: towercancerresearch@toweroncology.com
-
Duarte, California, Vereinigte Staaten, 91010
- Aktiv, nicht rekrutierend
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Vereinigte Staaten, 92618
- Aktiv, nicht rekrutierend
- City of Hope at Irvine Lennar
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Cedars-Sinai Medical Center
-
Hauptermittler:
- Justin M. Darrah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-Mail: Cancer.trial.info@cshs.org
-
-
Connecticut
-
Derby, Connecticut, Vereinigte Staaten, 06418
- Rekrutierung
- Smilow Cancer Hospital-Derby Care Center
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Fairfield, Connecticut, Vereinigte Staaten, 06824
- Rekrutierung
- Smilow Cancer Hospital Care Center-Fairfield
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Glastonbury, Connecticut, Vereinigte Staaten, 06033
- Rekrutierung
- Smilow Cancer Hospital Care Center at Glastonbury
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Greenwich, Connecticut, Vereinigte Staaten, 06830
- Rekrutierung
- Smilow Cancer Hospital Care Center at Greenwich
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Guilford, Connecticut, Vereinigte Staaten, 06437
- Rekrutierung
- Smilow Cancer Hospital Care Center - Guilford
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hartford, Connecticut, Vereinigte Staaten, 06105
- Rekrutierung
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Rekrutierung
- Yale University
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
North Haven, Connecticut, Vereinigte Staaten, 06473
- Rekrutierung
- Yale-New Haven Hospital North Haven Medical Center
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Stamford, Connecticut, Vereinigte Staaten, 06902
- Rekrutierung
- Smilow Cancer Hospital Care Center at Long Ridge
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Torrington, Connecticut, Vereinigte Staaten, 06790
- Rekrutierung
- Smilow Cancer Hospital-Torrington Care Center
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Trumbull, Connecticut, Vereinigte Staaten, 06611
- Rekrutierung
- Smilow Cancer Hospital Care Center-Trumbull
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Waterbury, Connecticut, Vereinigte Staaten, 06708
- Rekrutierung
- Smilow Cancer Hospital-Waterbury Care Center
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Waterford, Connecticut, Vereinigte Staaten, 06385
- Rekrutierung
- Smilow Cancer Hospital Care Center - Waterford
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- Rekrutierung
- Helen F Graham Cancer Center
-
Hauptermittler:
- Gregory A. Masters
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-623-4450
- E-Mail: lbarone@christianacare.org
-
Newark, Delaware, Vereinigte Staaten, 19713
- Rekrutierung
- Medical Oncology Hematology Consultants PA
-
Hauptermittler:
- Gregory A. Masters
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-623-4450
- E-Mail: lbarone@christianacare.org
-
-
Georgia
-
Albany, Georgia, Vereinigte Staaten, 31701
- Rekrutierung
- Phoebe Putney Memorial Hospital
-
Hauptermittler:
- Locke J. Bryan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 229-312-0405
- E-Mail: ga_cares@augusta.edu
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University Hospital/Winship Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Hauptermittler:
- Jonathon B. Cohen
-
Atlanta, Georgia, Vereinigte Staaten, 30303
- Rekrutierung
- Grady Health System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Hauptermittler:
- Jonathon B. Cohen
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Rekrutierung
- Emory University Hospital Midtown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-946-7447
-
Hauptermittler:
- Jonathon B. Cohen
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Rekrutierung
- Emory Saint Joseph's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-851-7115
-
Hauptermittler:
- Jonathon B. Cohen
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Rekrutierung
- Augusta University Medical Center
-
Hauptermittler:
- Locke J. Bryan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 706-721-2388
- E-Mail: ga_cares@augusta.edu
-
Johns Creek, Georgia, Vereinigte Staaten, 30097
- Rekrutierung
- Emory Johns Creek Hospital
-
Hauptermittler:
- Jonathon B. Cohen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-5714
- E-Mail: m.lisa.hwang@emory.edu
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Rekrutierung
- Saint Luke's Cancer Institute - Boise
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Boise, Idaho, Vereinigte Staaten, 83706
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Boise
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Caldwell, Idaho, Vereinigte Staaten, 83605
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Caldwell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Rekrutierung
- Kootenai Health - Coeur d'Alene
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Rekrutierung
- Saint Luke's Cancer Institute - Fruitland
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Rekrutierung
- Saint Luke's Cancer Institute - Meridian
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Luke's Cancer Institute - Nampa
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Nampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Rekrutierung
- Kootenai Clinic Cancer Services - Post Falls
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Rekrutierung
- Kootenai Clinic Cancer Services - Sandpoint
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
-
Illinois
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Rekrutierung
- Illinois CancerCare-Bloomington
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Canton, Illinois, Vereinigte Staaten, 61520
- Rekrutierung
- Illinois CancerCare-Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Rekrutierung
- Illinois CancerCare-Carthage
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hauptermittler:
- Carlos Galvez
-
Chicago, Illinois, Vereinigte Staaten, 60606
- Rekrutierung
- Alliance for Clinical Trials in Oncology
-
Hauptermittler:
- Anne W. Beaven
-
Kontakt:
- Anne W. Beaven
- E-Mail: beaven@med.unc.edu
-
Danville, Illinois, Vereinigte Staaten, 61832
- Rekrutierung
- Carle at The Riverfront
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Cancer Care Specialists of Illinois - Decatur
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Decatur Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Dixon, Illinois, Vereinigte Staaten, 61021
- Rekrutierung
- Illinois CancerCare-Dixon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 815-285-7800
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Carle Physician Group-Effingham
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Crossroads Cancer Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Rekrutierung
- Illinois CancerCare-Eureka
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Evanston, Illinois, Vereinigte Staaten, 60201
- Rekrutierung
- NorthShore University HealthSystem-Evanston Hospital
-
Hauptermittler:
- Amy Y. Wang
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Rekrutierung
- Illinois CancerCare-Galesburg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Glenview, Illinois, Vereinigte Staaten, 60026
- Rekrutierung
- NorthShore University HealthSystem-Glenbrook Hospital
-
Hauptermittler:
- Amy Y. Wang
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Highland Park, Illinois, Vereinigte Staaten, 60035
- Rekrutierung
- NorthShore University HealthSystem-Highland Park Hospital
-
Hauptermittler:
- Amy Y. Wang
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Rekrutierung
- Illinois CancerCare-Kewanee Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Rekrutierung
- Illinois CancerCare-Macomb
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Rekrutierung
- Carle Physician Group-Mattoon/Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Mount Vernon, Illinois, Vereinigte Staaten, 62864
- Rekrutierung
- SSM Health Good Samaritan
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 618-899-1894
- E-Mail: gayla.hall@ssmhealth.com
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Cancer Care Center of O'Fallon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Rekrutierung
- Illinois CancerCare-Ottawa Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Rekrutierung
- Illinois CancerCare-Pekin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Rekrutierung
- Illinois CancerCare-Peoria
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peru, Illinois, Vereinigte Staaten, 61354
- Rekrutierung
- Illinois CancerCare-Peru
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Rekrutierung
- Illinois CancerCare-Princeton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Shiloh, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Memorial Hospital East
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-747-9912
- E-Mail: dschwab@wustl.edu
-
Hauptermittler:
- Brad S. Kahl
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Springfield Clinic
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Rekrutierung
- Springfield Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-528-7541
- E-Mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Rekrutierung
- Carle Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Washington, Illinois, Vereinigte Staaten, 61571
- Rekrutierung
- Illinois CancerCare - Washington
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
-
Indiana
-
Crown Point, Indiana, Vereinigte Staaten, 46307
- Rekrutierung
- Northwest Cancer Center - Crown Point
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-836-6879
- E-Mail: CancerResearch@powershealth.org
-
Dyer, Indiana, Vereinigte Staaten, 46311
- Rekrutierung
- Northwest Oncology LLC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-924-8178
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Hobart, Indiana, Vereinigte Staaten, 46342
- Rekrutierung
- Northwest Cancer Center - Hobart
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-947-1795
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Hobart, Indiana, Vereinigte Staaten, 46342
- Rekrutierung
- Saint Mary Medical Center
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-836-6875
- E-Mail: CancerResearch@COMHS.org
-
Indianapolis, Indiana, Vereinigte Staaten, 46312
- Rekrutierung
- Saint Catherine Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-9171
- E-Mail: protocols@AllianceNCTN.org
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Munster, Indiana, Vereinigte Staaten, 46321
- Rekrutierung
- The Community Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-836-3349
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Munster, Indiana, Vereinigte Staaten, 46321
- Rekrutierung
- Women's Diagnostic Center - Munster
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-934-8869
- E-Mail: mnicholson@comhs.org
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Valparaiso, Indiana, Vereinigte Staaten, 46383
- Rekrutierung
- Northwest Cancer Center - Valparaiso
-
Hauptermittler:
- Maria T. Grosse-Perdekamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 219-836-6875
- E-Mail: CancerResearch@COMHS.org
-
-
Iowa
-
Ames, Iowa, Vereinigte Staaten, 50010
- Rekrutierung
- Mary Greeley Medical Center
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Ames, Iowa, Vereinigte Staaten, 50010
- Rekrutierung
- McFarland Clinic - Ames
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-239-4734
- E-Mail: ksoder@mcfarlandclinic.com
-
Ankeny, Iowa, Vereinigte Staaten, 50023
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Boone, Iowa, Vereinigte Staaten, 50036
- Suspendiert
- McFarland Clinic - Boone
-
Carroll, Iowa, Vereinigte Staaten, 51401
- Rekrutierung
- Saint Anthony Regional Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-689-7658
- E-Mail: sbenson@iora.org
-
Hauptermittler:
- Seema Harichand-Herdt
-
Clive, Iowa, Vereinigte Staaten, 50325
- Rekrutierung
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- Broadlawns Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-282-2200
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- Mercy Medical Center - Des Moines
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Richard L. Deming
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- Iowa Methodist Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-6727
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- Rekrutierung
- McFarland Clinic - Trinity Cancer Center
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- Rekrutierung
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Hauptermittler:
- Seema Harichand-Herdt
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-282-2921
- E-Mail: trials@missioncancer.com
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Hauptermittler:
- Eric Mou
-
Jefferson, Iowa, Vereinigte Staaten, 50129
- Suspendiert
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Vereinigte Staaten, 50158
- Rekrutierung
- McFarland Clinic - Marshalltown
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Waukee, Iowa, Vereinigte Staaten, 50263
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
-
Kansas
-
Hays, Kansas, Vereinigte Staaten, 67601
- Rekrutierung
- HaysMed
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-623-5774
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Rekrutierung
- University of Kansas Cancer Center
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Lawrence, Kansas, Vereinigte Staaten, 66044
- Rekrutierung
- Lawrence Memorial Hospital
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-505-2800
- E-Mail: Stephanie.Norris@LMH.ORG
-
Leavenworth, Kansas, Vereinigte Staaten, 66048
- Suspendiert
- Veteran Administration Eastern Kansas Healthcare
-
Olathe, Kansas, Vereinigte Staaten, 66061
- Rekrutierung
- The University of Kansas Cancer Center - Olathe
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-1569
- E-Mail: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Vereinigte Staaten, 66210
- Rekrutierung
- University of Kansas Cancer Center-Overland Park
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Pittsburg, Kansas, Vereinigte Staaten, 66762
- Rekrutierung
- Freeman Physician Group of Pittsburg
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- E-Mail: BNMathew@freemanhealth.com
-
Salina, Kansas, Vereinigte Staaten, 67401
- Rekrutierung
- Salina Regional Health Center
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-452-7038
- E-Mail: mleepers@srhc.com
-
Topeka, Kansas, Vereinigte Staaten, 66606
- Rekrutierung
- University of Kansas Health System Saint Francis Campus
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-295-8000
-
Westwood, Kansas, Vereinigte Staaten, 66205
- Rekrutierung
- University of Kansas Hospital-Westwood Cancer Center
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- The James Graham Brown Cancer Center at University of Louisville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-562-3429
-
Hauptermittler:
- Hassaan Yasin
-
Louisville, Kentucky, Vereinigte Staaten, 40245
- Rekrutierung
- UofL Health Medical Center Northeast
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-852-2755
- E-Mail: ctoinfo@louisville.edu
-
Hauptermittler:
- Hassaan Yasin
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Bay City, Michigan, Vereinigte Staaten, 48706
- Rekrutierung
- McLaren Cancer Institute-Bay City
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health Medical Center - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health Medical Center - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- Rekrutierung
- McLaren Cancer Institute-Clarkston
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Rekrutierung
- Wayne State University/Karmanos Cancer Institute
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-527-6266
- E-Mail: ctoadmin@karmanos.org
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Rekrutierung
- Weisberg Cancer Treatment Center
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Farmington Hills, Michigan, Vereinigte Staaten, 48336
- Rekrutierung
- Corewell Health Farmington Hills Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Andrew A. Muskovitz
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Genesys Hurley Cancer Institute
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Hurley Medical Center
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Flint, Michigan, Vereinigte Staaten, 48532
- Rekrutierung
- McLaren Cancer Institute-Flint
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Flint, Michigan, Vereinigte Staaten, 48503
- Suspendiert
- Genesee Hematology Oncology PC
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Cancer Hematology Centers - Flint
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Lansing, Michigan, Vereinigte Staaten, 48912
- Rekrutierung
- University of Michigan Health - Sparrow Lansing
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 517-364-3712
- E-Mail: harsha.trivedi@umhsparrow.org
-
Lapeer, Michigan, Vereinigte Staaten, 48446
- Rekrutierung
- McLaren Cancer Institute-Lapeer Region
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Rekrutierung
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Macomb, Michigan, Vereinigte Staaten, 48044
- Rekrutierung
- Henry Ford Saint John Hospital - Macomb Medical
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-343-3166
- E-Mail: kforman1@hfhs.org
-
Mount Pleasant, Michigan, Vereinigte Staaten, 48858
- Rekrutierung
- McLaren Cancer Institute-Central Michigan
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Petoskey, Michigan, Vereinigte Staaten, 49770
- Rekrutierung
- McLaren Cancer Institute-Northern Michigan
-
Hauptermittler:
- Dipenkumar Modi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Corewell Health William Beaumont University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Andrew A. Muskovitz
-
Saginaw, Michigan, Vereinigte Staaten, 48604
- Suspendiert
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- Rekrutierung
- MyMichigan Medical Center Saginaw
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Tawas City, Michigan, Vereinigte Staaten, 48764
- Rekrutierung
- MyMichigan Medical Center Tawas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Troy, Michigan, Vereinigte Staaten, 48085
- Rekrutierung
- Corewell Health Beaumont Troy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Andrew A. Muskovitz
-
West Branch, Michigan, Vereinigte Staaten, 48661
- Suspendiert
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Huron Gastroenterology PC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
-
Minnesota
-
Bemidji, Minnesota, Vereinigte Staaten, 56601
- Rekrutierung
- Sanford Joe Lueken Cancer Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-333-5000
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Brainerd, Minnesota, Vereinigte Staaten, 56401
- Rekrutierung
- Essentia Health Saint Joseph's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Rekrutierung
- Essentia Health - Deer River Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Rekrutierung
- Essentia Health Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Rekrutierung
- Essentia Health Hibbing Clinic
-
Hauptermittler:
- Bret E. Friday
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Rekrutierung
- Saint John's Hospital - Healtheast
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Rekrutierung
- Abbott-Northwestern Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Rekrutierung
- Hennepin County Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Saint Cloud, Minnesota, Vereinigte Staaten, 56303
- Rekrutierung
- Coborn Cancer Center at Saint Cloud Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-229-4907
- E-Mail: coborncancercenter@centracare.com
-
Hauptermittler:
- Donald J. Jurgens
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Rekrutierung
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Rekrutierung
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- Rekrutierung
- United Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
Sandstone, Minnesota, Vereinigte Staaten, 55072
- Rekrutierung
- Essentia Health Sandstone
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Rekrutierung
- Essentia Health Virginia Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Rekrutierung
- Minnesota Oncology Hematology PA-Woodbury
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- Yan Ji
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Rekrutierung
- Saint Francis Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-Mail: sfmc@sfmc.net
-
Chesterfield, Missouri, Vereinigte Staaten, 63017
- Rekrutierung
- Saint Luke's Hospital
-
Hauptermittler:
- Mark J. Fesler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-205-6936
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63376
- Rekrutierung
- Siteman Cancer Center at Saint Peters Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Brad S. Kahl
-
Creve Coeur, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Siteman Cancer Center at West County Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Brad S. Kahl
-
Kansas City, Missouri, Vereinigte Staaten, 64154
- Rekrutierung
- University of Kansas Cancer Center - North
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Kansas City, Missouri, Vereinigte Staaten, 64128
- Rekrutierung
- Kansas City Veterans Affairs Medical Center
-
Hauptermittler:
- Suman Kambhampati
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-525-1483
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Rekrutierung
- University Health Truman Medical Center
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-404-4375
-
Kansas City, Missouri, Vereinigte Staaten, 64116
- Rekrutierung
- University of Kansas Cancer Center - Briarcliff
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
-
Lee's Summit, Missouri, Vereinigte Staaten, 64064
- Rekrutierung
- University of Kansas Cancer Center - Lee's Summit
-
Hauptermittler:
- Marc S. Hoffmann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
North Kansas City, Missouri, Vereinigte Staaten, 64116
- Suspendiert
- University of Kansas Cancer Center at North Kansas City Hospital
-
Springfield, Missouri, Vereinigte Staaten, 65804
- Rekrutierung
- Mercy Hospital Springfield
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 417-269-4520
-
Springfield, Missouri, Vereinigte Staaten, 65807
- Rekrutierung
- CoxHealth South Hospital
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 417-269-4520
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Brad S. Kahl
-
St Louis, Missouri, Vereinigte Staaten, 63128
- Rekrutierung
- Mercy Hospital South
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-525-6042
- E-Mail: Danielle.Werle@mercy.net
-
St Louis, Missouri, Vereinigte Staaten, 63129
- Rekrutierung
- Siteman Cancer Center-South County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Brad S. Kahl
-
St Louis, Missouri, Vereinigte Staaten, 63136
- Rekrutierung
- Siteman Cancer Center at Christian Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Brad S. Kahl
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Rekrutierung
- Community Hospital of Anaconda
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Billings, Montana, Vereinigte Staaten, 59101
- Rekrutierung
- Billings Clinic Cancer Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-996-2663
- E-Mail: research@billingsclinic.org
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Rekrutierung
- Bozeman Health Deaconess Hospital
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Rekrutierung
- Benefis Sletten Cancer Institute
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Rekrutierung
- Logan Health Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Missoula, Montana, Vereinigte Staaten, 59804
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue, Nebraska, Vereinigte Staaten, 68123
- Rekrutierung
- Nebraska Medicine-Bellevue
-
Hauptermittler:
- Julie M. Vose
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Kearney, Nebraska, Vereinigte Staaten, 68845
- Rekrutierung
- Fred and Pamela Buffett Cancer Center - Kearney
-
Hauptermittler:
- Julie M. Vose
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Rekrutierung
- University of Nebraska Medical Center
-
Hauptermittler:
- Julie M. Vose
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Omaha, Nebraska, Vereinigte Staaten, 68118
- Rekrutierung
- Nebraska Medicine-Village Pointe
-
Hauptermittler:
- Julie M. Vose
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-5600
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-Mail: cancer.research.nurse@dartmouth.edu
-
Hauptermittler:
- Charles Gaulin
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14263
- Rekrutierung
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Hauptermittler:
- Chelsea Peterson
-
Camillus, New York, Vereinigte Staaten, 13031
- Rekrutierung
- Hematology Oncology Associates of CNY at Camillus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-472-7504
-
Hauptermittler:
- Steven M. Duffy
-
East Syracuse, New York, Vereinigte Staaten, 13057
- Rekrutierung
- Hematology Oncology Associates of Central New York-East Syracuse
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-472-7504
-
Hauptermittler:
- Steven M. Duffy
-
Mineola, New York, Vereinigte Staaten, 11501
- Rekrutierung
- NYU Langone Hospital - Long Island
-
Hauptermittler:
- Peter Martin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-Mail: cancertrials@nyulangone.org
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Hauptermittler:
- Peter Martin
-
Kontakt:
- Site Public Contact
- E-Mail: CancerTrials@nyulangone.org
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- NYP/Weill Cornell Medical Center
-
Hauptermittler:
- Jia Ruan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-746-1848
-
Rochester, New York, Vereinigte Staaten, 14642
- Rekrutierung
- University of Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 585-275-5830
-
Hauptermittler:
- Paul M. Barr
-
Webster, New York, Vereinigte Staaten, 14580
- Rekrutierung
- Wilmot Cancer Institute at Webster
-
Hauptermittler:
- Paul M. Barr
-
Kontakt:
- Site Public Contact
- E-Mail: WCICTOresearch@urmc.rochester.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- Rekrutierung
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-Mail: cancerclinicaltrials@med.unc.edu
-
Hauptermittler:
- Anne W. Beaven
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Hauptermittler:
- Matthew S. McKinney
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Rekrutierung
- Sanford Bismarck Medical Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Broadway Medical Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Vereinigte Staaten, 58103
- Rekrutierung
- Essentia Health Cancer Center-South University Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Roger Maris Cancer Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-234-6161
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- Ohio State University Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-293-5066
- E-Mail: Jamesline@osumc.edu
-
Hauptermittler:
- David A. Bond
-
-
Oklahoma
-
Lawton, Oklahoma, Vereinigte Staaten, 73505
- Rekrutierung
- Cancer Centers of Southwest Oklahoma Research
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-231-4440
-
Hauptermittler:
- Taha Al-Juhaishi
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-Mail: ou-clinical-trials@ouhsc.edu
-
Hauptermittler:
- Taha Al-Juhaishi
-
Tulsa, Oklahoma, Vereinigte Staaten, 74146
- Rekrutierung
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 918-505-3200
-
Hauptermittler:
- Mark B. Jennings
-
-
Oregon
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Rekrutierung
- Providence Newberg Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Ontario, Oregon, Vereinigte Staaten, 97914
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Oregon City, Oregon, Vereinigte Staaten, 97045
- Rekrutierung
- Providence Willamette Falls Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Portland, Oregon, Vereinigte Staaten, 97213
- Rekrutierung
- Providence Portland Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Portland, Oregon, Vereinigte Staaten, 97225
- Rekrutierung
- Providence Saint Vincent Medical Center
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rekrutierung
- Rhode Island Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
Hauptermittler:
- Adam J. Olszewski
-
Westerly, Rhode Island, Vereinigte Staaten, 02891
- Rekrutierung
- Smilow Cancer Hospital Care Center - Westerly
-
Hauptermittler:
- Shalin Kothari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
-
South Carolina
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Rekrutierung
- Prisma Health Cancer Institute - Spartanburg
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 843-792-9321
- E-Mail: hcc-clinical-trials@musc.edu
-
Hauptermittler:
- Katherine Antel
-
Easley, South Carolina, Vereinigte Staaten, 29640
- Rekrutierung
- Prisma Health Cancer Institute - Easley
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health Cancer Institute - Faris
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health Cancer Institute - Butternut
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Rekrutierung
- Prisma Health Cancer Institute - Eastside
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greer, South Carolina, Vereinigte Staaten, 29650
- Rekrutierung
- Prisma Health Cancer Institute - Greer
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Rekrutierung
- Prisma Health Cancer Institute - Seneca
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Rekrutierung
- Sanford Cancer Center Oncology Clinic
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Rekrutierung
- Sanford USD Medical Center - Sioux Falls
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Rekrutierung
- Huntsman Cancer Institute/University of Utah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-424-2100
- E-Mail: cancerinfo@hci.utah.edu
-
Hauptermittler:
- Harsh Shah
-
-
Vermont
-
Saint Johnsbury, Vermont, Vereinigte Staaten, 05819
- Rekrutierung
- Dartmouth Cancer Center - North
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-Mail: cancer.research.nurse@hitchcock.org
-
Hauptermittler:
- Charles Gaulin
-
-
Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23235
- Rekrutierung
- VCU Massey Cancer Center at Stony Point
-
Kontakt:
- Site Public Contact
- E-Mail: ctoclinops@vcu.edu
-
Hauptermittler:
- Bruce O. Hough
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Rekrutierung
- VCU Massey Comprehensive Cancer Center
-
Hauptermittler:
- Bruce O. Hough
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-Mail: CTOclinops@vcu.edu
-
-
Washington
-
Edmonds, Washington, Vereinigte Staaten, 98026
- Rekrutierung
- Swedish Cancer Institute-Edmonds
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Issaquah, Washington, Vereinigte Staaten, 98029
- Rekrutierung
- Swedish Cancer Institute-Issaquah
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Vereinigte Staaten, 98122
- Rekrutierung
- Swedish Medical Center-First Hill
-
Hauptermittler:
- Alison K. Conlin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
-
Wisconsin
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- Rekrutierung
- ThedaCare Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Yazhini Vallatharasu
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- Rekrutierung
- ThedaCare Regional Medical Center - Appleton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Yazhini Vallatharasu
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Rekrutierung
- Duluth Clinic Ashland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Rekrutierung
- Marshfield Medical Center-EC Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Johnson Creek, Wisconsin, Vereinigte Staaten, 53038
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Hauptermittler:
- Priyanka Pophali
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Rekrutierung
- Gundersen Lutheran Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-775-2385
- E-Mail: cancerctr@gundersenhealth.org
-
Hauptermittler:
- Michael O. Ojelabi
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Hauptermittler:
- Priyanka Pophali
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Vereinigte Staaten, 53718
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Hauptermittler:
- Priyanka Pophali
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Rekrutierung
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Medical College of Wisconsin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-805-3666
-
Hauptermittler:
- Mehdi Hamadani
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Rekrutierung
- Marshfield Medical Center - Minocqua
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- Rekrutierung
- ProHealth D N Greenwald Center
-
Kontakt:
- Site Public Contact
- E-Mail: research.institute@phci.org
-
Hauptermittler:
- Timothy R. Wassenaar
-
New Berlin, Wisconsin, Vereinigte Staaten, 53151
- Rekrutierung
- Froedtert and MCW Moorland Reserve Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-805-0505
-
Hauptermittler:
- Mehdi Hamadani
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- ProHealth Oconomowoc Memorial Hospital
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7878
-
Rice Lake, Wisconsin, Vereinigte Staaten, 54868
- Rekrutierung
- Marshfield Medical Center-Rice Lake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54482
- Rekrutierung
- Marshfield Medical Center-River Region at Stevens Point
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- UW Cancer Center at ProHealth Care
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-5539
- E-Mail: Chanda.miller@phci.org
-
Weston, Wisconsin, Vereinigte Staaten, 54476
- Rekrutierung
- Marshfield Medical Center - Weston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
• Histologically confirmed mantle cell lymphoma with cyclin D1 (BCL1) expression by immunohistochemical stains and/or evidence of CCND1 rearrangement or t(11;14)(q13;q32) as confirmed by the enrolling center (such as by fluorescence in situ hybridization [FISH], polymerase chain reaction [PCR]/sequencing, karyotype). Patients with cyclin D1 and/or t(11;14) negative mantle cell lymphoma with an expression profile suggesting a diagnosis of mantle cell lymphoma [MCL] such as SOX11 expression are also eligible
-
Any stage allowed (stage I-IV)
- Patient must have at least one objective measurable disease parameter by PET or CT. Measurable disease in the liver is required if the liver is the only site of lymphoma OR bone marrow involvement by MCL
- Steroids for management of mantle cell lymphoma are allowed up to a dose of prednisone 100mg/day (or equivalent) for up to 7 days prior to registration
- No prior systemic treatment for mantle cell lymphoma
- No prior radiation treatment for stage I MCL
- No prior exposure to a BTK inhibitor or anti-CD20 monoclonal antibody
- No prior stem cell transplant
- Age >= 70 years OR age >= 60 to < 70 years with comorbidities precluding autologous stem cell transplantation (autoSCT) including at least one of the following: a) cardiac ejection fraction (EF) <= 45%, b) diffusing capacity for carbon monoxide <= 60% predicted; c) creatinine clearance < 70 but >= 30ml/minute (min); d) Eastern Cooperative Oncology Group (ECOG) performance status of 2, which poses an unacceptable risk of toxicity for high-dose therapy and stem cell transplantation; or e) Cumulative Illness Rating Scales (CIRS) total score > 6
- ECOG Performance Status 0-2
- Absolute neutrophil count (ANC) >= 750/mm^3 (without growth factor support within 7 days)
- Platelet count >= 75,000/mm^3 (or >= 50,000/mm^3 if thrombocytopenia is due to lymphoma) without growth factor support or transfusion within 7 days
- Creatinine clearance >= 30 mL/ min determined by either: a) Estimation using the Cockcroft-Gault equation or b) Measurement by nuclear medicine scan or 24 hour urine collection
- Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome)
- Aspartate transferase (AST) / alanine transaminase (ALT) =< 3 x ULN
- Patients should not be considered candidates for stem cell transplant or must have declined a stem cell transplant strategy
- No clinically significant cardiovascular disease including the following
-
Unstable angina within 3 months before registration
-
New York Heart Association class III or IV congestive heart failure
-
History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)
-
Known QT correction formula (QTcF) > 480 msecs based on Fredericia's formula (unless pacemaker in place)
-
History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- No active Hepatitis B or Hepatitis C infection. Patients with prior hepatitis B virus (HBV) exposure (positive HBV core antibody and/or surface antigen) are eligible if they have no detectable viral load, and are taking appropriate prophylactic antiviral therapy to prevent reactivation. Patients with history of hepatitis C virus (HCV) are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- No history of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
- No history of stroke or intracranial hemorrhage within 6 months prior to registration
- No disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. Patient must be able to swallow pills
- Potential trial participants should have recovered from major surgery
- No vaccination with a live vaccine within 35 days prior to registration
- No hypersensitivity to zanubrutinib or rituximab or any of the other ingredients of the study drugs
- Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study.
- Patients on strong CYP3A4 inducers must discontinue the drug 14 days prior to registration.
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Induction therapy (Zanubrutinib, rituximab)
Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial. |
Undergo blood sample collection Given IV Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Undergo PET
Andere Namen:
Undergo colonoscopy Undergo observation Undergo EGD
Andere Namen:
Given PO undergo bone marrow biopsy Given IV |
|
Experimental: Arm A (Zanubrutinib)
Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
Undergo blood sample collection Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Undergo PET
Andere Namen:
Undergo colonoscopy Undergo observation Undergo EGD
Andere Namen:
Given PO undergo bone marrow biopsy Given IV |
|
Aktiver Komparator: ARM B (Observation)
Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
Undergo blood sample collection Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Undergo PET
Andere Namen:
Undergo colonoscopy Undergo observation Undergo EGD
Andere Namen:
Given PO undergo bone marrow biopsy Given IV |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival (PFS) 1 (Arm A)
Zeitfenster: Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years
|
Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and mantle cell lymphoma (MCL) International Prognostic Index (IPI) score. The primary analysis for non-inferiority will be based on an intent-to-treat (ITT) analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring. |
Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years
|
|
Progression-free survival (PFS) 2 (Arm B)
Zeitfenster: Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years
|
Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and MCL IPI score. The primary analysis for non-inferiority will be based on an ITT analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring. |
Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall survival (OS) (Arms A and B)
Zeitfenster: Time from randomization until death from any cause, assessed up to 10 years
|
Kaplan-Meier methodology will be used to estimate the distributions of OS by treatment arm and log-rank test statistics will be used to compare these distributions between the two treatment arms. Cox Proportional Hazards models may be used to further evaluate covariates of interest with OS, including assessment of treatment effects when adjusting for other known risk factors in the model. |
Time from randomization until death from any cause, assessed up to 10 years
|
|
Incidence of adverse events
Zeitfenster: Up to 10 years
|
Will be evaluated and captured using the CTCAE 5.0, where the type and severity grade of each adverse event will be collected and tabulated within each of the treatment arms. Perceived attribution to study treatment will also be captured. The analysis population for this secondary endpoint will include all patients who are registered and randomized on the study and receive at least one dose of study treatment. Adverse events will be monitored continuously throughout the course of the study as well as analyzed at the time of the final primary endpoint analysis. Summary statistics and frequency tables will be used to describe the distributions of adverse events. Rates of adverse events occurring in compared across the treatment arms with chi-squared tests Tolerability will also be evaluated, summarizing rates of dose delays or modifications, reasons patients end treatment, and time to end of active treatment. |
Up to 10 years
|
|
Overall response rate (ORR, complete + partial remission)
Zeitfenster: up to 10 years
|
Will be assessed using Lugano criteria. ORR to induction is defined as the number of patients with complete or partial remission at the end of induction divided by the number of patients who receive at least one dose of the induction regimen. ORR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete or partial remission after restart of zanubrutinib divided by the number of patients that restart zanubrutinib after first disease progression following randomization. The frequencies and rates of tumor response categories will be summarized by treatment arm for response to induction as well as response to restart of zanubrutinib (Arm B only). ORR to induction and ORR to restart of zanubrutinib (Arm B only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and ORR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at final analysis. |
up to 10 years
|
|
Complete response rate (CR)
Zeitfenster: Up to 10 years
|
Will be assessed using Lugano criteria. CR to induction is defined as the number of patients with complete remission at the end of induction divided by the number of eligible patients who receive at least one dose of the induction regimen. CR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete remission after restart of zanubrutinib divided by the number of eligible patients that restart zanubrutinib after first disease progression following randomization. CR to induction and CR to restart of zanubrutinib (Arm B patients only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and CR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at the time of the final analysis. |
Up to 10 years
|
|
Event-free survival (EFS) 1
Zeitfenster: Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
For EFS1, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS. |
Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
|
Event-free survival (EFS) 2
Zeitfenster: Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
For EFS2, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS. |
Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
Mitarbeiter und Ermittler
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom
- Hämische und lymphatische Krankheiten
- Lymphom, Mantelzelle
- Verwaltung des Gesundheitswesens
- Aminosäuren, Peptide und Proteine
- Proteine
- Untersuchungstechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Minimal invasive chirurgische Verfahren
- Qualität der Gesundheitsversorgung
- Kohlenhydrate
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Diagnosetechniken, chirurgisch
- Endoskopie, gastrointestinal
- Diagnosetechniken, Verdauungssystem
- Endoskopie
- Chirurgische Verfahren des Verdauungssystems
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Desoxyglucose
- Desoxyzucker
- Ergebnisbewertung, Gesundheitsversorgung
- Ergebnis- und Prozessbewertung, Gesundheitswesen
- Antikörper, monoklonale, murine abgeleitete
- Rituximab
- Fluordesoxyglucose F18
- Zanubrutinib
- Koloskopie
- Magnetresonanzspektroskopie
- Wachvolles Warten
- Endoskopie, Verdauungssystem
Andere Studien-ID-Nummern
- A052101
- NCI-2023-03577 (Andere Kennung: NCI Clinical Trial Reporting Program)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .